Aspen Pharmacare Holdings Limited Logo

Aspen Pharmacare Holdings Limited

APNHF

(2.2)
Stock Price

12,25 USD

0.39% ROA

9.48% ROE

365.67x PER

Market Cap.

95.590.643.388,74 USD

42.96% DER

0.1% Yield

10.56% NPM

Aspen Pharmacare Holdings Limited Stock Analysis

Aspen Pharmacare Holdings Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Aspen Pharmacare Holdings Limited Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (34%), which means it has a small amount of debt compared to the ownership it holds

3 ROE

The stock's ROE falls within an average range (6.65%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (7.97%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 Assets Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

6 Dividend Growth

The company's dividend growth has exhibited a remarkable upward trend over the past three years, consistently delivering higher payouts to shareholders.

7 Dividend

The company's consistent dividend payments over the past three years indicate a strong commitment to delivering returns to investors.

8 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

10 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Aspen Pharmacare Holdings Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Aspen Pharmacare Holdings Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Buy
4 Stoch RSI Buy

Aspen Pharmacare Holdings Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Aspen Pharmacare Holdings Limited Revenue
Year Revenue Growth
2003 1.900.805.000
2004 2.201.721.000 13.67%
2005 2.814.597.000 21.77%
2006 3.449.340.000 18.4%
2007 4.025.854.000 14.32%
2008 4.682.500.000 14.02%
2009 8.441.400.000 44.53%
2010 9.619.200.000 12.24%
2011 12.383.200.000 22.32%
2012 15.255.800.000 18.83%
2013 19.308.000.000 20.99%
2014 29.515.100.000 34.58%
2015 36.100.000.000 18.24%
2016 35.600.000.000 -1.4%
2017 41.213.000.000 13.62%
2018 38.314.000.000 -7.57%
2019 38.872.000.000 1.44%
2020 38.647.000.000 -0.58%
2021 37.766.000.000 -2.33%
2022 38.606.000.000 2.18%
2023 40.709.000.000 5.17%
2024 4.617.194.400 -781.68%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Aspen Pharmacare Holdings Limited Research and Development Expenses
Year Research and Development Expenses Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 42.800.000 100%
2014 53.300.000 19.7%
2015 200.000.000 73.35%
2016 200.000.000 0%
2017 188.000.000 -6.38%
2018 111.000.000 -69.37%
2019 211.000.000 47.39%
2020 195.000.000 -8.21%
2021 260.000.000 25%
2022 433.000.000 39.95%
2023 214.000.000 -102.34%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Aspen Pharmacare Holdings Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2003 365.592.000
2004 435.557.000 16.06%
2005 550.800.000 20.92%
2006 658.087.000 16.3%
2007 745.094.000 11.68%
2008 272.300.000 -173.63%
2009 587.500.000 53.65%
2010 740.400.000 20.65%
2011 827.300.000 10.5%
2012 1.101.800.000 24.91%
2013 1.366.000.000 19.34%
2014 1.652.500.000 17.34%
2015 2.900.000.000 43.02%
2016 1.400.000.000 -107.14%
2017 1.433.000.000 2.3%
2018 1.615.000.000 11.27%
2019 1.651.000.000 2.18%
2020 1.598.000.000 -3.32%
2021 1.843.000.000 13.29%
2022 1.481.000.000 -24.44%
2023 1.677.000.000 11.69%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Aspen Pharmacare Holdings Limited EBITDA
Year EBITDA Growth
2003 446.853.000
2004 553.760.000 19.31%
2005 493.424.000 -12.23%
2006 894.742.000 44.85%
2007 1.076.629.000 16.89%
2008 1.660.900.000 35.18%
2009 2.619.200.000 36.59%
2010 2.980.300.000 12.12%
2011 3.346.800.000 10.95%
2012 4.168.600.000 19.71%
2013 5.255.900.000 20.69%
2014 8.693.600.000 39.54%
2015 9.500.000.000 8.49%
2016 10.500.000.000 9.52%
2017 11.141.000.000 5.75%
2018 11.652.000.000 4.39%
2019 11.000.000.000 -5.93%
2020 10.680.000.000 -3%
2021 9.849.000.000 -8.44%
2022 10.705.000.000 8%
2023 10.572.000.000 -1.26%
2024 1.148.347.200 -820.63%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Aspen Pharmacare Holdings Limited Gross Profit
Year Gross Profit Growth
2003 860.838.000
2004 1.058.107.000 18.64%
2005 1.390.619.000 23.91%
2006 1.660.293.000 16.24%
2007 1.941.646.000 14.49%
2008 2.171.300.000 10.58%
2009 3.877.300.000 44%
2010 4.476.500.000 13.39%
2011 5.613.500.000 20.25%
2012 7.276.300.000 22.85%
2013 9.230.700.000 21.17%
2014 13.721.900.000 32.73%
2015 17.300.000.000 20.68%
2016 17.900.000.000 3.35%
2017 19.896.000.000 10.03%
2018 19.686.000.000 -1.07%
2019 19.698.000.000 0.06%
2020 19.333.000.000 -1.89%
2021 17.789.000.000 -8.68%
2022 18.306.000.000 2.82%
2023 18.408.000.000 0.55%
2024 2.033.740.800 -805.13%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Aspen Pharmacare Holdings Limited Net Profit
Year Net Profit Growth
2003 270.645.000
2004 355.580.000 23.89%
2005 186.421.000 -90.74%
2006 637.796.000 70.77%
2007 717.323.000 11.09%
2008 862.900.000 16.87%
2009 1.340.400.000 35.62%
2010 1.989.600.000 32.63%
2011 2.577.800.000 22.82%
2012 2.817.800.000 8.52%
2013 3.520.100.000 19.95%
2014 5.007.600.000 29.7%
2015 5.200.000.000 3.7%
2016 4.300.000.000 -20.93%
2017 5.128.000.000 16.15%
2018 6.037.000.000 15.06%
2019 6.463.000.000 6.59%
2020 4.664.000.000 -38.57%
2021 4.806.000.000 2.95%
2022 6.488.000.000 25.92%
2023 5.228.000.000 -24.1%
2024 505.377.600 -934.47%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Aspen Pharmacare Holdings Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2003 1
2004 1 100%
2005 1 0%
2006 2 100%
2007 2 50%
2008 2 0%
2009 4 33.33%
2010 5 25%
2011 6 20%
2012 6 16.67%
2013 8 14.29%
2014 11 30%
2015 11 9.09%
2016 9 -22.22%
2017 11 18.18%
2018 13 15.38%
2019 14 7.14%
2020 10 -40%
2021 11 0%
2022 14 28.57%
2023 12 -27.27%
2024 1 -1000%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Aspen Pharmacare Holdings Limited Free Cashflow
Year Free Cashflow Growth
2003 124.672.000
2004 250.040.000 50.14%
2005 478.356.000 47.73%
2006 109.805.000 -335.64%
2007 273.842.000 59.9%
2008 107.100.000 -155.69%
2009 -2.614.500.000 104.1%
2010 740.500.000 453.07%
2011 1.605.700.000 53.88%
2012 290.000.000 -453.69%
2013 -335.900.000 186.34%
2014 1.807.000.000 118.59%
2015 2.400.000.000 24.71%
2016 400.000.000 -500%
2017 3.856.000.000 89.63%
2018 -1.211.000.000 418.41%
2019 2.419.000.000 150.06%
2020 5.570.000.000 56.57%
2021 3.394.000.000 -64.11%
2022 2.677.000.000 -26.78%
2023 2.339.000.000 -14.45%
2024 -21.785.400 10836.55%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Aspen Pharmacare Holdings Limited Operating Cashflow
Year Operating Cashflow Growth
2003 385.946.000
2004 498.737.000 22.62%
2005 652.876.000 23.61%
2006 401.769.000 -62.5%
2007 708.560.000 43.3%
2008 652.400.000 -8.61%
2009 1.292.100.000 49.51%
2010 2.033.000.000 36.44%
2011 2.445.900.000 16.88%
2012 2.908.400.000 15.9%
2013 3.986.100.000 27.04%
2014 3.836.300.000 -3.9%
2015 4.800.000.000 20.08%
2016 3.200.000.000 -50%
2017 6.487.000.000 50.67%
2018 7.017.000.000 7.55%
2019 6.002.000.000 -16.91%
2020 8.260.000.000 27.34%
2021 6.825.000.000 -21.03%
2022 5.374.000.000 -27%
2023 5.520.000.000 2.64%
2024 134.206.800 -4013.06%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Aspen Pharmacare Holdings Limited Capital Expenditure
Year Capital Expenditure Growth
2003 261.274.000
2004 248.697.000 -5.06%
2005 174.520.000 -42.5%
2006 291.964.000 40.23%
2007 434.718.000 32.84%
2008 545.300.000 20.28%
2009 3.906.600.000 86.04%
2010 1.292.500.000 -202.25%
2011 840.200.000 -53.83%
2012 2.618.400.000 67.91%
2013 4.322.000.000 39.42%
2014 2.029.300.000 -112.98%
2015 2.400.000.000 15.45%
2016 2.800.000.000 14.29%
2017 2.631.000.000 -6.42%
2018 8.228.000.000 68.02%
2019 3.583.000.000 -129.64%
2020 2.690.000.000 -33.2%
2021 3.431.000.000 21.6%
2022 2.697.000.000 -27.22%
2023 3.181.000.000 15.22%
2024 155.992.200 -1939.2%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Aspen Pharmacare Holdings Limited Equity
Year Equity Growth
2003 794.975.000
2004 1.066.481.000 25.46%
2005 1.106.768.000 3.64%
2006 1.713.295.000 35.4%
2007 2.382.479.000 28.09%
2008 3.257.705.000 26.87%
2009 4.263.000.000 23.58%
2010 10.886.200.000 60.84%
2011 13.287.300.000 18.07%
2012 17.398.100.000 23.63%
2013 22.798.900.000 23.69%
2014 28.876.100.000 21.05%
2015 34.161.500.000 15.47%
2016 42.500.000.000 19.62%
2017 43.127.000.000 1.45%
2018 50.095.000.000 13.91%
2019 54.213.000.000 7.6%
2020 69.217.000.000 21.68%
2021 65.627.000.000 -5.47%
2022 70.942.000.000 7.49%
2023 86.236.000.000 17.74%
2024 84.861.000.000 -1.62%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Aspen Pharmacare Holdings Limited Assets
Year Assets Growth
2003 1.681.705.000
2004 2.109.656.000 20.29%
2005 3.136.305.000 32.73%
2006 4.269.421.000 26.54%
2007 7.531.962.000 43.32%
2008 10.848.595.000 30.57%
2009 12.521.800.000 13.36%
2010 19.800.900.000 36.76%
2011 26.797.400.000 26.11%
2012 31.718.500.000 15.51%
2013 45.421.700.000 30.17%
2014 82.547.400.000 44.98%
2015 88.417.300.000 6.64%
2016 104.300.000.000 15.23%
2017 116.300.000.000 10.32%
2018 132.836.000.000 12.45%
2019 122.316.000.000 -8.6%
2020 133.169.000.000 8.15%
2021 109.684.000.000 -21.41%
2022 111.375.000.000 1.52%
2023 134.284.000.000 17.06%
2024 139.155.000.000 3.5%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Aspen Pharmacare Holdings Limited Liabilities
Year Liabilities Growth
2003 886.730.000
2004 1.043.175.000 15%
2005 2.029.537.000 48.6%
2006 2.543.645.000 20.21%
2007 5.142.521.000 50.54%
2008 7.529.789.000 31.7%
2009 8.258.800.000 8.83%
2010 8.914.700.000 7.36%
2011 13.510.100.000 34.01%
2012 14.320.400.000 5.66%
2013 22.622.800.000 36.7%
2014 53.671.300.000 57.85%
2015 54.255.800.000 1.08%
2016 61.800.000.000 12.21%
2017 73.200.000.000 15.57%
2018 82.741.000.000 11.53%
2019 68.103.000.000 -21.49%
2020 63.952.000.000 -6.49%
2021 44.057.000.000 -45.16%
2022 40.433.000.000 -8.96%
2023 48.048.000.000 15.85%
2024 54.294.000.000 11.5%

Aspen Pharmacare Holdings Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
5.16
Net Income per Share
0.59
Price to Earning Ratio
365.67x
Price To Sales Ratio
41.66x
POCF Ratio
284.61
PFCF Ratio
1348.33
Price to Book Ratio
1.13
EV to Sales
52.17
EV Over EBITDA
196.47
EV to Operating CashFlow
356.37
EV to FreeCashFlow
1688.54
Earnings Yield
0
FreeCashFlow Yield
0
Market Cap
95,59 Bil.
Enterprise Value
119,71 Bil.
Graham Number
50.29
Graham NetNet
-74.18

Income Statement Metrics

Net Income per Share
0.59
Income Quality
1.28
ROE
0
Return On Assets
0.06
Return On Capital Employed
0.12
Net Income per EBT
0.78
EBT Per Ebit
0.75
Ebit per Revenue
0.18
Effective Tax Rate
0.22

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.44
Operating Profit Margin
0.18
Pretax Profit Margin
0.14
Net Profit Margin
0.11

Dividends

Dividend Yield
0
Dividend Yield %
0.1
Payout Ratio
0.32
Dividend Per Share
0.21

Operating Metrics

Operating Cashflow per Share
0.76
Free CashFlow per Share
0.16
Capex to Operating CashFlow
0.79
Capex to Revenue
0.12
Capex to Depreciation
2.63
Return on Invested Capital
0
Return on Tangible Assets
0
Days Sales Outstanding
0
Days Payables Outstanding
1267.47
Days of Inventory on Hand
5218.89
Receivables Turnover
0
Payables Turnover
0.29
Inventory Turnover
0.07
Capex per Share
0.6

Balance Sheet

Cash per Share
27,77
Book Value per Share
191,00
Tangible Book Value per Share
29.37
Shareholders Equity per Share
191
Interest Debt per Share
82.27
Debt to Equity
0.43
Debt to Assets
0.26
Net Debt to EBITDA
39.58
Current Ratio
1.81
Tangible Asset Value
13,05 Bil.
Net Current Asset Value
-10,21 Bil.
Invested Capital
112030000000
Working Capital
19,71 Bil.
Intangibles to Total Assets
0.52
Average Receivables
6,28 Bil.
Average Payables
7,48 Bil.
Average Inventory
18479000000
Debt to Market Cap
0.38

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Aspen Pharmacare Holdings Limited Dividends
Year Dividends Growth
2017 0
2018 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Aspen Pharmacare Holdings Limited Profile

About Aspen Pharmacare Holdings Limited

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.

CEO
Mr. Stephen Bradley Saad BCom,
Employee
8.867
Address
Aspen Place
Durban,

Aspen Pharmacare Holdings Limited Executives & BODs

Aspen Pharmacare Holdings Limited Executives & BODs
# Name Age
1 Mr. Reginald Haman Grad. Dip., MBA, ND, NHD, PGDBA
Group Chief Corporate Officer & Executive Director
70
2 Ms. Sibongakonke Nkosi
Investor Relations Manager
70
3 Mr. Sean M. Capazorio
Group Chief Financial Officer & Executive Director
70
4 Mr. Samer Kassem
Chief Executive Officer of Aspen Global Incorporated
70
5 Mr. Michael Guy Attridge B.Com., CA(SA)
Group Chief Advisor
70
6 Mr. Trevor Julian Ziman
Regional Chief Executive Officer of Asia Pacific
70
7 Ms. Lorraine Hill
Group Chief Operations Officer
70
8 Mr. Stephen Bradley Saad BCom, CA(SA)
Group Chief Executive Officer & Executive Director
70
9 Ms. Zizipho Mmango
Group Chief Strategic Development Officer
70
10 Ms. Raeesa Khan
Group Company Secretary & Chief of Staff
70

Aspen Pharmacare Holdings Limited Competitors